Norcantharidin Nanostructured Lipid Carrier (NCTD-NLC) Suppresses the Viability of Human Hepatocellular Carcinoma HepG2 Cells and Accelerates the Apoptosis

Figure 3

The HPLC detection onto the groups of NCTD-NLC gavage, NCTD gavage, NCTD-NLC tail vein injection, and NCTD tail vein injection to figure out the NCTD content in the heart, liver, spleen, lung, kidney, and plasma. (a) HPLC profiles. (b) The NCTD HPLC profiles of the heart, liver, spleen, lung, kidney, and plasma in the NCTD-NLC gavage group. (c) The NCTD HPLC profiles of the heart, liver, spleen, lung, kidney, and plasma in the NCTD gavage group. (d) The NCTD HPLC profiles of the heart, liver, spleen, lung, kidney, and plasma in the NCTD-NLC tail vein injection group. (e) The NCTD HPLC profiles of the heart, liver, spleen, lung, kidney, and plasma in the NCTD tail vein injection group.

(a)

(b)

(c)

(d)

(e)